PCOS Patients' Immune Alterations

Who can take part

• Female subjects aged 18-45 years
• Voluntarily participate in the experiment, willing to sign the informed consent
• According to the Rotterdam consensus, polycystic ovarian syndrome (PCOS) needs to meet the presence of two of three of the following criteria: oligo-anovulation, hyperandrogenism, and polycystic ovaries (≥ 12 follicles measuring 2-9 mm in diameter and/or an ovarian volume > 10 mL in at least one ovary)

Who cannot take part

• Hypoglycemic drugs that may affect insulin resistance and androgen levels, including thiazolidinedione, metformin, SGLT-2i, acarbose, and glucagon-like peptide-1 receptor agonist (GLP-1RA), have been used in the past 3 months
• Take letrozole, clomiphene, oral contraceptives, glucocorticoids, gonadotropins, gonadotropin-releasing hormone agonists, antiandrogens (spironolactone, cyproterone acetate, flutamide, etc.), and other medications for PCOS treatment within the last 3 months
• Ovulation disorders caused by premature ovarian failure, pituitary amenorrhea, hypothalamic amenorrhea, and thyroid dysfunction (hyperthyroidism, hypothyroidism)
• Congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, adrenal tumors, and other diseases causing hyperandrogenemia
• Type 1 diabetes, monogenic mutation diabetes, diabetes due to pancreatic injury or other secondary diabetes
• History of malignant tumor
• Severe infection, severe anemia, neutropenia, and other chronic diseases of the system
• Mental illness, dementia, or other cognitive behavioral problems
• Female patients younger than 18 years old or older than 45 years old
• Severe liver and kidney dysfunction (more than 3 times the normal value)
• Patients undergoing total hysterectomy or ovarian adnexectomy
• Pregnant or lactating patients
• Female patients with a BMI less than 20kg/m2